PDCD1 and neoplasm: The burgeoning immune checkpoint inhibitors (ICIs), such as CTLA4, PD-1 and PD-L1 antibodies, in combination with immune stimulation supports that host immune system could serve as a therapeutic modulator for tumor development and progression.